The effect of PYY (3-36) on bone turnover markers in obese patient with type 2 diabetes
- Resource Type
- Authors
- Alexiadou, K; Choudhury, S; Malallah, K; Shin, E; Doyle, C; Khir, M; Busbridge, M; Courtney, A; Tan, TM
- Source
- Diabetes UK Professional Conference 2022
- Subject
- Endocrinology & Metabolism
Science & Technology
1701 Psychology
digestive, oral, and skin physiology
1103 Clinical Sciences
Life Sciences & Biomedicine
1117 Public Health and Health Services
- Language
Background: Gut hormones have emerged as new promising therapies for the treatment of obesity and type 2 diabetes as well as viable alternatives to bariatric surgery. PYY has mainly been studied for its effect on appetite suppression and lately for its role in diabetes remission post-bariatric surgery. Animal data have suggested that PYY may act on the bone remodelling process by increasing bone resorption. Aims: The aim of our study was to assess the effect of PYY infusion on bone turn over markers in obese patients with type 2 diabetes. Methods: Ten obese patients with type 2 diabetes on diet or one hypoglycaemic agent were enrolled in the study. An infusion of PYY (3-36) was administered daily for up to 16 hours for a duration of 4 weeks. Metabolic profiling at fasting state and during a Mixed Meal Test (MMT) was performed prior to the initiation of the infusion and at the end of 4 weeks. Bone markers (plasma P1NP, CTX, OC) were measured at the beginning and the end of the 4 weeks both at fasting state and during the MMT. Urinary NTX was measured at fasting state only. Results: There was no significant difference in bone markers before and after the intervention. P1NP and CTX reduced significantly during the MMT compared to the fasting state both prior and 4 weeks after the infusion of PYY (3-36). Conclusions: Infusion of PYY (3-36) for 4 weeks does not affect the bone turnover markers in obese patients with type 2 diabetes. P1NP and CTX reduce significantly as a response to nutrient intake. PYY (3-36) could be developed as treatment for obesity with type 2 diabetes without negative implications for bone health.